XML 50 R45.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Business Combinations (Details Textual) (USD $) | 12 Months Ended | 1 Months Ended | 12 Months Ended |  | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jan. 31, 2011 CyDex medication licensee product | Dec. 31, 2014 CyDex employee_equivalent | Dec. 31, 2013 CyDex | Jan. 31, 2011 CyDex Complete technology | Jan. 31, 2011 CyDex Trademark and trade name | Dec. 31, 2014 CyDex Customer relationships | Jan. 31, 2011 CyDex Customer relationships
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Number of FDA-approved medications |  |  |  | 6 |  |  |  |  |  |
Number of licensees |  |  |  | 4 |  |  |  |  |  |
Cash paid to CyDex shareholders |  |  |  | $ 31,572,000 |  |  |  |  |  |
Percentage of related revenue |  |  |  |  | 20.00% |  |  |  |  |
Amount exceeds to get related revenue for CyDex share holders |  |  |  |  | 15,000,000 |  |  |  |  |
Percentage of related revenue additional |  |  |  |  | 10.00% |  |  |  |  |
Aggregate CyDex-related revenue |  |  |  |  | 35,000,000 |  |  |  |  |
Discount rate used to estimate future cash flows |  |  |  | 21.50% |  |  | 20.50% | 20.50% |  | 21.50%
Gain (loss) on asset disposal | 5,000 | (17,000) | (456,000) |  | 500,000 | 0 |  |  |  |
Number of employees required |  |  |  |  | 5 |  |  |  |  |
Investments for acquiring employees |  |  |  |  | 1,500,000 |  |  |  |  |
Business combination, weighted-average amortizaiton period intangible assets |  |  |  |  | 20 years |  |  |  | 20 years |
In-process research and development |  |  |  | $ 3,200,000 |  |  |  |  |  |
Number of acquirees in-process research and development products |  |  |  | 2 |  |  |  |  |  |

X
- Definition Additional percentage of contingent consideration. + References No definition available. + Details
Name: | lgnd_AdditionalPercentageOfContingentConsideration
Namespace Prefix: | lgnd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue for contingent consideration. + References No definition available. + Details
Name: | lgnd_AmountOfRevenueForContingentConsideration
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate + References No definition available. + Details
Name: | lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
Namespace Prefix: | lgnd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Number of Acquirees In-Process Research and Development Products + References No definition available. + Details
Name: | lgnd_BusinessCombinationNumberOfAcquireesInProcessResearchAndDevelopmentProducts
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, in Process Research and Development + References No definition available. + Details
Name: | lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Limit of revenue for contingent consideration for additional percentage. + References No definition available. + Details
Name: | lgnd_LimitOfRevenueForContingentConsiderationForAdditionalPercentage
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Minimum investment annually. + References No definition available. + Details
Name: | lgnd_MinimumInvestmentAnnually
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of employees required. + References No definition available. + Details
Name: | lgnd_NumberOfEmployeesRequired
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of FDA-approved medications. + References No definition available. + Details
Name: | lgnd_NumberOfFdaApprovedMedications
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of licensees. + References No definition available. + Details
Name: | lgnd_NumberOfLicensees
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of contingent consideration. + References No definition available. + Details
Name: | lgnd_PercentageOfContingentConsideration
Namespace Prefix: | lgnd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration